At Canary, we utilize cutting-edge technology to decode genomics and support clinical decision-making with unprecedented accuracy. Our dedicated team has pioneered the development of a remarkably comprehensive genomic profiling (CGP) test and smaller focused panels which are meticulously validated for absolute sensitivity and specificity and held to the highest standards, as demonstrated by our Clinical Laboratory Improvement Amendments (CLIA) certification and College of American Pathologists (CAP) accreditation. We also provide extraordinarily useful ctDNA tests.

Our CGP test analyzes 1091 genes associated with cancer and also tests for drug sensitivities, providing oncologists and patients with crucial insights into personalized treatment strategies. Beyond the laboratory, our team is committed to providing personalized support throughout the entire diagnostic journey. We offer direct assistance to physicians in interpreting complex genomic reports, ensuring that treatment decisions are based on the latest scientific evidence and tailored to each patient’s unique genetic profile.

At the heart of everything we do is a profound commitment to improving patient outcomes and enhancing quality of life. We understand the significant impact of a cancer diagnosis on individuals and their loved ones. Therefore, alongside our rigorous focus on the accuracy and reliability of our tests, our team extends guidance and support to the families of patients, helping them navigate the complexities of cancer treatment and genetic information with empathy and clarity.

At Canary, we are not just advancing genomic medicine; we are redefining it to empower patients, physicians, and families with the knowledge and support they need to make informed decisions and achieve better outcomes in the fight against cancer.

We are proud of the quality of our tests and are delighted that the oncology community recognizes its power and utility.

Thank you for trusting us with the molecular diagnosis you and your family deserve.